Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
QT

NASDAQ · QTRX

Quanterix Corporation

Healthcare · Medical - Devices

$2.72

Up+$0.19 (+6.99%)

Updated Sep 17, 2026, 1:07 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
352.9M
P/E ratio
-4.17
Dividend yield
0.00%
52-week range
$2.15 – $8.77
Volume
1.6M
Avg. volume
639.37K

Price performance

QTRX price history

1M range · 0 trading sessions · Daily adjusted prices

QTRX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest QTRX news

The latest Smart Investors Daily articles mentioning QTRX.

Stock researchCompany · Overview

QTRX research

Overview

Company profile and research snapshot.

Company profile

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.67
Implied upside
—
Analysts
—
QTRX recent ratings
DateFirmRatingTarget
Aug 17, 2026Canaccord GenuityHold—
Aug 11, 2026TD CowenHold—
May 7, 2026TD CowenHold—
Apr 20, 2026Canaccord GenuityHold—
Dec 22, 2025Canaccord GenuityHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

BILLERICA, Mass., September 14, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications.

Yahoo · Sep 4, 2026

Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By